Patients With hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated With Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-Based Regimen

Anticancer Research - Greece

doi 10.21873/anticanres.13000